Perspective Therapeutics Introduces “Pre-Targeting” Theranostic Technology Platform
Retrieved on:
Thursday, February 1, 2024
Stony Brook University, Toxicity, National Cancer Institute, Research, Riitta Jallinoja, NIH, CB7, CATX, Patient, Safety, Diagnosis, Adma, CEA, Ligand, Therapy, Radiation, Journal, Assistant professor, Cancer, Neoplasm, Radiology, Bangladesh Technical Education Board, Radioactive decay, Nuclear medicine, Vaccine
This antibody is chemically modified to include the CB7 chemical entity and accumulates over time at the tumor site.
Key Points:
- This antibody is chemically modified to include the CB7 chemical entity and accumulates over time at the tumor site.
- Then, a radionuclide held tightly by Perspective’s proprietary chelator attached to an Adma group is administered.
- The research conducted at Stony Brook University refines the understanding of the potential of the proprietary CB7-Adma pre-targeting platform for image-guided radionuclide therapy for oncology.
- The technology was first described by Stony Brook University researchers, Jacob L. Houghton, Ph.D. and Vilma I.J.